Gino In

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

• University of Southern California: Chief Medical Oncology Fellow

• Acral lentiginous melanoma. Part I. Epidemiology, etiology, clinical presentation, and diagnosis. J Am Acad Dermatol. 2026 Feb; 94(2):421-432.. View in PubMed
• Acral lentiginous melanoma. Part II. Staging, surgical management, the role of systemic therapy, shortcomings, and future directions. J Am Acad Dermatol. 2026 Feb; 94(2):435-446.. View in PubMed
• RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). J Clin Oncol. 2025 Nov 20; 43(33):3589-3599.. View in PubMed
• Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov; 31(11):3933.. View in PubMed
• Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov; 31(11):3668-3674.. View in PubMed
• A case of cutaneous angiosarcoma with intradermal metastases responding to PD-1 inhibition-based immunotherapy. JAAD Case Rep. 2025 Oct; 64:67-70.. View in PubMed
• Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025 Aug 10; 43(23):2658.. View in PubMed
• Ancestry and somatic profile predict acral melanoma origin and prognosis. medRxiv. 2025 Aug 08.. View in PubMed
• Are guidelines guiding? A mixed methods study examining the integration of ASCO fertility discussion guidelines in practice among oncologists and adolescents and young adults at an NCI-designated Comprehensive Cancer Center. J Cancer Surviv. 2025 Jun 19.. View in PubMed
• Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025 May 20; 43(15):1800-1809.. View in PubMed
• Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma. Pigment Cell Melanoma Res. 2025 May; 38(3):e70027.. View in PubMed
• Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. Br J Dermatol. 2025 Jan 24; 192(2):316-326.. View in PubMed
• Chemoimmunotherapy in Advanced, PD-1 Refractory Cutaneous Squamous Cell Carcinoma: Insights From Two Immunocompromised Patient Cases. Case Rep Oncol Med. 2025; 2025:4443916.. View in PubMed
• A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma. Gynecol Oncol. 2024 Sep; 188:13-21.. View in PubMed
• Clinicopathologic comparison of basal cell carcinoma among a diverse patient population in Los Angeles County. Skin Health Dis. 2024 Aug; 4(4):e379.. View in PubMed
• Influence of Anatomic Locations of T1b Melanomas and Patient Age on Outcomes. J Drugs Dermatol. 2024 May 01; 23(5):306-310.. View in PubMed
• Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights. Clin Exp Dermatol. 2024 Mar 21; 49(4):392-394.. View in PubMed
• Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis. 2024 02 14; 15(2):140.. View in PubMed
• Social health, activity behaviors, and quality of life among young adult cancer survivors: Protocol for a prospective observational study. PLoS One. 2024; 19(11):e0309924.. View in PubMed
• Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. NPJ Precis Oncol. 2023 Nov 14; 7(1):120.. View in PubMed
• Prevalence and correlates of skin examination among ethnically diverse young adult survivors of childhood cancer. Cancer Med. 2023 04; 12(7):8557-8566.. View in PubMed
• Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.. View in PubMed
• A retrospective analysis of rates of dermatology follow-up and new skin cancer diagnosis among solid organ transplant recipients during the COVID-19 pandemic. JAAD Int. 2023 Mar; 10:53-54.. View in PubMed
• Intraocular Spread of Ocular Surface Squamous Neoplasia Presenting as a Postoperative Anterior Chamber Opacity after Excisional Biopsy. Case Rep Ophthalmol. 2023 Jan-Dec; 14(1):194-202.. View in PubMed
• Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830.. View in PubMed
• Development of a core outcome set for basal cell carcinoma. J Am Acad Dermatol. 2022 09; 87(3):573-581.. View in PubMed
• Examining low rates of dermatology visits in solid organ transplant recipients. J Am Acad Dermatol. 2022 06; 86(6):1369-1372.. View in PubMed
• Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study. Clin Breast Cancer. 2022 06; 22(4):e558-e566.. View in PubMed
• Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. J Immunother Cancer. 2022 05; 10(5).. View in PubMed
• Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers (Basel). 2022 Mar 15; 14(6).. View in PubMed
• Disparities in nonmelanoma skin cancer in Hispanic/Latino patients based on Mohs micrographic surgery defect size: A multicenter retrospective study. J Am Acad Dermatol. 2022 02; 86(2):353-358.. View in PubMed
• Social networks of oncology clinicians as a means for increasing survivorship clinic referral. Commun Med (Lond). 2022; 2:89.. View in PubMed
• Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015. Pigment Cell Melanoma Res. 2021 11; 34(6):1049-1061.. View in PubMed
• Cutaneous Malignancies of the Head and Neck. Hematol Oncol Clin North Am. 2021 10; 35(5):991-1008.. View in PubMed
• Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma. Genome Med. 2021 08 16; 13(1):130.. View in PubMed
• 18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma. Clin Nucl Med. 2021 Aug 01; 46(8):e436-e437.. View in PubMed
• A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma. Cureus. 2021 Jun; 13(6):e15480.. View in PubMed
• PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol. 2021 Jun; 147(6):1803-1811.. View in PubMed
• The time to offer treatments for COVID-19. Expert Opin Investig Drugs. 2021 May; 30(5):505-518.. View in PubMed
• Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Res. 2021 04 01; 31(2):162-172.. View in PubMed
• Rapidly Progressive Porocarcinoma of the Ear and Multidisciplinary Approach to Management. Dermatol Surg. 2021 03 01; 47(3):404-406.. View in PubMed
• The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021 02 08; 23(1):40-47.. View in PubMed
• COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract. 2021 Feb; 27(2):90-94.. View in PubMed
• Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center. Cancer Treat Res Commun. 2021; 26:100273.. View in PubMed
• Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2021 01; 246(1):31-39.. View in PubMed
• Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020 Aug 18; 11(33):3118-3128.. View in PubMed
• Skin cancer and dermatoses in a majority-Hispanic population of solid organ transplant recipients. J Am Acad Dermatol. 2020 Aug; 83(2):607-610.. View in PubMed
• Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study. Pediatr Blood Cancer. 2020 03; 67(3):e28090.. View in PubMed
• Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget’s disease. Cancer Med. 2020 02; 9(4):1441-1450.. View in PubMed
• Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. Int Ophthalmol Clin. 2020; 60(2):77-89.. View in PubMed
• Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766.. View in PubMed
• Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Rep. 2019 Jun 20; 12(6).. View in PubMed
• Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 04 12; 10(1):1693.. View in PubMed
• Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatol Surg. 2019 02; 45(2):254-267.. View in PubMed
• Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006.. View in PubMed
• Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 10; 44(10):1247-1261.. View in PubMed
• Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3).. View in PubMed
• Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550.. View in PubMed
• Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3).
• Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017.
• Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57.. View in PubMed
• Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355.

• Lenz, Heinz-Josef
• Daneshmand, Siamak
• Ulaner, Gary
• Matsuo, Koji
• Armstrong, April
• Cockburn, Myles